Search / Trial NCT00002292

A Study of Two Forms of Pentamidine in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS

Launched by LYPHOMED · Aug 30, 2001

Trial Information

Current as of December 06, 2024

Completed

Keywords

Aids Related Opportunistic Infections Pneumonia, Pneumocystis Carinii Pentamidine Injections, Intravenous Administration, Inhalation Aerosols Acquired Immunodeficiency Syndrome

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Exclusion Criteria
  • Co-existing Condition:
  • Patients with the following are excluded:
  • Previous history of adverse reaction to pentamidine.
  • History of asthma.
  • Pulmonary Kaposi's sarcoma.
  • Patients with the following are excluded:
  • Previous history of adverse reaction to pentamidine.
  • History of asthma.
  • Pulmonary Kaposi's sarcoma.
  • Inability to understand the consent procedure.
  • All patients hospitalized at Cedars-Sinai Medical Center with AIDS and possible Pneumocystis carinii pneumonia (PCP) will be eligible.
  • Patients with HIV antibody or AIDS and a clinical presentation suggesting PCP are eligible.

About Lyphomed

Lypohomed is a leading clinical trial sponsor dedicated to advancing innovative therapies and improving patient outcomes in the pharmaceutical and biotechnology sectors. With a focus on high-quality research and development, Lypohomed collaborates with a network of healthcare professionals and institutions to design and execute rigorous clinical trials. The organization emphasizes ethical practices, regulatory compliance, and patient safety, ensuring that all studies are conducted with the utmost integrity. Through its commitment to scientific excellence and collaboration, Lypohomed aims to bring transformative treatments to market and address unmet medical needs.

Locations

Rosemont, Illinois, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials